BGI Co-Win
VC Fund
Shenzhen, China
BGI Co-Win is a VC fund in Shenzhen focused on Biotechnology and Health Care. BGI Co-Win is the corporate venture capital arm of BGI and is based in Shenzhen, China.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries BGI Co-Win invests in
Stages BGI Co-Win invests in
Countries BGI Co-Win invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Investment Focus
Industry
- Biotechnology 11 (69%)
- Health Care 8 (50%)
- Medical 7 (44%)
- Pharmaceutical 7 (44%)
- Medical Device 4 (25%)
Stage
- Series A 5 (31%)
- Series B 4 (25%)
- Seed 2 (13%)
- Series C 2 (13%)
- Angel 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Ji Changtao
Partner
|
Partner | Total investments: 1 | Find email | |
|
Liu Yu
Founding partner
|
Founding partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Aijie Boya is a medical instrument and magnetic solid-phase material company. | $13.7M / Feb 12, 2025 | |
|
|
LeadBio Tech is a biotechnology company that specializes in the development of bioartificial blood vessel medical devices. | $13.7M / Series A / Nov 13, 2023 | |
|
|
Burning Point Medical develops pharmaceutical products for hypertensive and spastic pain disorders. Burning Point's products aim to treat hypertension, and relieve chest pain and spastic pains, enabling healthcare professionals to prescribe more effective treatments to their patients. | Series B / Jun 16, 2023 | |
|
|
Ubrigene is driven by the advancement of gene and cell therapy technologies through research and development represented by AAV vectors. It can provide a comprehensive solution for gene therapy industrialization. | $14.7M / Series C / Dec 23, 2022 | |
|
|
Weike Bio is a gene therapy drug development company. | Angel / Dec 20, 2022 | |
|
|
Yingshu Life is a research and development manufacturer of minimally invasive medical devices. | Seed / Nov 22, 2022 | |
|
|
Hemu Gene is a gene therapy technology developer. It has two gene editing platforms: lentivirus, CRISPR and Cas. | $4.4M / Series A / Aug 16, 2022 | |
|
|
YZY Bio is a biotechnology company that develops anti-tumor bispecific antibodies based on breakthrough discoveries in molecular biology, enabling patients with major diseases to obtain more efficient treatment solutions. | $38.7M / Series B / Sep 13, 2021 | |
|
|
Realmind Biotech develops Vitro diagnostic devices intended for medical assessments. From miniaturized chemiluminescence analyzer, to fully automatic chemiluminescence POCT, then to microdroplet chip POCT, till this day the company has laid out a comprehensive blueprint of multiple innovative IVD platforms. | Seed / Jul 19, 2021 | |
|
|
Ab&B Biotech focuses on the research and development of innovative human vaccines and multivalent vaccines. | $92.7M / Series C / Jul 16, 2021 | |
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does BGI Co-Win invest in?
BGI Co-Win invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 16 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact BGI Co-Win?
Public channels for BGI Co-Win include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BGI Co-Win?
The team at BGI Co-Win includes Ji Changtao (Partner) and Liu Yu (Founding partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!